Introduction
Serglycin is the major intracellular proteoglycan of hematopoietic cells. [1] [2] [3] Serglycin mRNA expression has been demonstrated in several myeloid and lymphoid cell lines, [4] [5] [6] [7] and serglycin immunoreactivity has been observed in myeloid cells and cell lines 8, 9 as well as in cell lines of lymphoid, mast cell, plasmacytoid and myelomonocytic origin. 10 The function of serglycin in the different types of cells is slowly becoming apparent. Initially, sulfation of the heparin side chains of serglycin was shown to be essential for localization of several mast cell proteases to granules. 11, 12 More recently, serglycin proved to be essential both for maturation of mast cell granules and for localization of granule proteins. 13 Furthermore, granzyme B was shown to be delivered from cytotoxic lymphocytes to target cells as a macromolecular complex with serglycin. 14 The amount of granzyme B but not granzyme A nor perforin in granules is reduced in T cells lacking serglycin and the ultrastructure of granules is slightly altered. 15 We recently showed that targeting of neutrophil elastase to azurophil granules depends on serglycin, whereas this is not the case for other granule proteins tested. 3 During differentiation of neutrophils in human bone marrow, serglycin mRNA expression and immunoreactivity is present only at the promyelocyte and immature myelocyte stage, whereas mature neutrophils are devoid of serglycin immunoreactivity and mRNA. 6, 9 This prompted us to investigate the expression of serglycin in the malignant counterpart of immature myeloid cells, the myeloblasts, in bone marrow samples from patients with acute myeloid leukemia (AML). Furthermore, we characterize the expression of serglycin in the malignant counterparts of other hematopoietic cell types that have been reported to express serglycin, for example, anaplastic large cell lymphoma (ALCL), natural killer cell (NK cell) lymphoma and acute lymphoblastic leukemia (ALL). The level of serglycin in plasma samples from patients with acute leukemia and Philadelphia chromosome (Ph1)-negative chronic myeloproliferative disorders was also investigated.
Materials and methods

Patient samples
Plasma was obtained from patients at diagnosis (patients with acute leukemia) or during treatment and follow up (patients with chronic myeloproliferative disorders) and from normal volunteers. AML, n ¼ 35; ALL, n ¼ 6; controls, n ¼ 22; idiopathic myelofibrosis, n ¼ 14; polycythemia vera, n ¼ 13; essential thrombocytosis, n ¼ 11. Formalin-fixed, paraffin-embedded specimens of bone marrow were obtained from 18 patients with AML (M1, n ¼ 5; M2, n ¼ 8; M3, n ¼ 1; M4, n ¼ 2; unclassified, n ¼ 2), 4 with T-ALL, 8 with B-ALL and from 1 patient without hematologic disease. In addition, samples from tumors were obtained from three patients with extranodal T/NK-cell lymphoma, nasal-type, and seven with ALCL (three anaplastic lymphoma kinase (ALK) negative, and four ALK positive). The samples were from the archives at the Department of Pathology, Rigshospitalet, University of Copenhagen, Denmark. All samples were reviewed by histology and immunohistology using standard panels of antibodies (CD34, CD117, myeloperoxidase (MPO), CD68 (PGM1), CD20, CD79a, CD10, TdT, CD3, CD5, CD4, CD8, CD56, TIA-1, Granzyme-B, CD30, ALK1) for classification in accordance with WHO guidelines (2001). Informed consent was obtained according to the permission and guidelines from the Local Ethics Committee.
ELISA
The amount of serglycin in plasma and bone marrow plasma samples was determined by a previously described ELISA. 9 The polyclonal rabbit antibody used for the ELISA was generated toward full-length, nonglycosylated, recombinant human serglycin. The ELISA has the same sensitivity for glycosylated and nonglycosylated serglycin. 9 Neutrophil elastase was measured by a commercially available ELISA (HyCult biotechnology, Uden, the Netherlands). MPO and Lysozyme levels were measured by ELISA as described previously. 16, 17 Immunohistochemistry Sections of formalin-fixed, paraffin-embedded biopsies were heated in a microwave oven (Milestone Micromed, Hacker
Instruments & Industries Inc., NJ, USA) in TEG buffer (pH 9) for 15 min and stained with a 1:300 dilution of affinity-purified polyclonal rabbit anti-serglycin immunoglobulin G 9 for 60 min at room temperature. Further processing was with the Techmate 500 Immunostainer (DAKO, Glostrup, Denmark), using the DAKO Envision K5007 kit.
Statistics
All statistics were performed with the SPSS 13.0 software (SPSS Inc., Chicago, IL, USA). Data were log10 transformed for the independent t-test, untransformed for multiple regression analysis.
Results
Serglycin is localized to leukemic blasts in bone marrow from patients with AML
In normal human bone marrow, serglycin is detectable only by immunohistochemistry at the promyelocyte and myelocyte stage, whereas mature neutrophils stain negative for serglycin (Figures 1g and h, 9 ). In bone marrow specimens from all 18 patients with AML, the vast majority of the abnormal leukemic blast cells showed cytoplasmic immunostaining for serglycin with a predominantly perinuclear, dot-like staining pattern, resembling that seen in promyelocytes from normal bone marrow (Figures 1a-f ). This staining corresponds to localization in the Golgi. 9 No differences could be detected in the pattern of serglycin immunoreactivity between different French-Ameri 
ALL cells are devoid of serglycin immunoreactivity
We next looked at the expression and localization of serglycin in bone marrow from 12 patients with ALL. No serglycin immunoreactivity was detected in bone marrow specimens from patients with either B-ALL or T-ALL except from a few scattered residual myeloid precursor cells (Figures 1i-l) .
Plasma serglycin is significantly higher in AML vs ALL patients, and no difference is seen between Ph1-negative chronic myeloproliferative disorders and normal controls
In order to assess whether the serglycin abundantly expressed in AML blasts is reflected in plasma, we quantitated the amount of serglycin in plasma from patients with AML and ALL. The samples were blinded, that is tested without knowledge of type of leukemia; all samples were tested in parallel. The mean concentration of serglycin in plasma from patients with AML (N ¼ 31) was more than 15 times higher than the mean for ALL patients (N ¼ 6) (Figure 2a) . The difference in plasma concentration of serglycin was statistically significant (Po0.001). These results are in accordance with the pattern of serglycin immunoreactivity in bone marrow specimens from patients with acute leukemia.
As the stage of maturation arrest in AML is reflected by the FAB classification, 18 we also tested the correlation between the plasma level of serglycin and FAB classification, as serglycin is expressed in a differentiation-specific manner. However, we could not detect any significant difference in serglycin level among the different FAB groups (data not shown). This is in agreement with the uniform level of serglycin immunoreactivity among bone marrow specimens from patients with different FAB types of AML (Figures 1a-f) . The plasma level of serglycin covered a wide range in patients with AML (Figure 2a ). Since serglycin is expressed by immature myeloid cells, we hypothesized that plasma serglycin would correlate with granule proteins expressed in myeloblasts and promyelocytes. Multiple regression was performed to test the relation between plasma serglycin and lysozyme (previously reported as a marker of myelopoiesis 19 ), MPO (a marker of azurophil granules 20 ) and neutrophil elastase (recently shown by us to be dependent on serglycin for granule localization in neutrophils 3 ). As seen in The level of serglycin in plasma from patients with Ph1-negative chronic myeloproliferative disorders did not differ from that of normal controls (Figure 2b) . This was true whether we analyzed the samples as a single group or divided into groups of patients with idiopathic myelofibrosis, polycythemia vera and essential thrombocytosis. Multiple regression correction for confounders such as length of disease or previous treatment did not reveal any differences among the patients (data not shown).
Serglycin is absent from granzyme B-positive T-and NK-cell lymphomas
We next examined serglycin expression in specimens from patients with cytotoxic T/NK cell lymphomas, including three with extranodal T/NK-cell lymphoma, nasal-type and seven with ALCL, four of which were positive for ALK. These types of lymphoma represent the malignant counterparts of cytotoxic lymphocytes, 21 known to harbor granzyme B in a macromolecular complex with serglycin in their granules. 14 We could not detect immunoreactivity for serglycin in the malignant cells in any of these samples (Figures 3a and c) . By contrast, granzyme B immunoreactivity was detected in the vast majority of malignant cells in both NK-cell lymphoma specimens and ALCL specimens, irrespective of ALK status (Figures 3b and d) .
Discussion
Serglycin proteoglycan is implicated in granule formation and localization of granule proteins in several different hematopoietic cell types. 3, [11] [12] [13] 15 We have shown that serglycin is present in promyelocytes and disappears as cells mature along the granulocytic lineage during normal myelopoiesis. 9 This prompted us to explore the expression of serglycin proteoglycan in bone marrow of AML patients and to compare with ALL patients and normal controls. We found strong immunoreactivity for serglycin in myeloblasts from untreated AML patients. In contrast, no ALL lymphoblasts were positive for serglycin. In normal bone marrow, serglycin was expressed predominantly in cells from the early stages of myelopoiesis, in particular promyelocytes ( Figure 1 ). This is consistent with serglycin being expressed predominantly in immature myeloid cells whether these are AML myeloblasts or cells from the early steps of normal myelopoiesis.
We hypothesized that plasma serglycin reflects the expression of serglycin in bone marrow cells in acute leukemia patients and might be used to discriminate between AML and ALL. We found statistically significant higher levels of serglycin in plasma from patients with AML compared with plasma from patients with ALL ( Figure 2a) . When an arbitrary cut-off at 0.5 (arbitrary units of the ELISA) was used, 32 out of 35 plasma samples from AML patients were above this level and all 6 out of 6 samples from ALL patients were at or below this level. This gives a positive predictive value of 100% and a negative predictive value of 67%, while the specificity in our population will be 100% and the sensitivity 91% in differentiating between patients with AML and ALL. The correlation between serglycin expression in bone marrow specimens from AML patients and the plasma level of serglycin in AML patients indicates that plasma serglycin originates predominantly from myeloid cells.
Chronic myeloproliferative disorders represent states with increased numbers of mature myeloid cells. 22 If only immature myeloid cells are positive for serglycin and if the plasma level of serglycin reflects the expression in immature myeloid cells, plasma serglycin in patients with Ph1-negative chronic myeloproliferative disorders would equal that in normal controls. Our data from patients with idiopathic myelofibrosis, polycythemia vera and essential thrombocytosis are in agreement with this ( Figure 2b ). The few patients with higher plasma levels of serglycin may represent patients with extramedullary hematopoiesis or with increased immature myeloid precursors in the bone marrow but we have no available data to substantiate this assumption. These findings indicate that the increase in numbers of mature myeloid cells in Ph1-negative chronic myeloproliferative disorders does not result in elevated plasma serglycin. This underscores that serglycin is expressed predominantly in immature myeloid cells and that these are the predominant source of serglycin in plasma. The fate of serglycin during maturation of neutrophils has not been determined. However, the previously described protease resistance of the serglycin protein core 23 has been questioned by several reports. 9, [24] [25] [26] Thus, degradation of serglycin inside the neutrophil granules, rich in proteases, is a likely explanation for lack of serglycin in granules of mature neutrophils. Patients with chronic myeloid leukemia were not included, since the level of promyelocytes in bone marrow and peripheral blood is often significantly elevated at diagnosis. Serglycin is thus a marker for immature myeloid cells, in contrast to MPO, which identifies all stages of myeloid cells from promyelocytes to mature neutrophils. This difference is emphasized by the lack of correlation between plasma serglycin and MPO in AML patients. Serglycin is not a marker of myelopoiesis per se, as seen by the low plasma serglycin in patients with Ph1-negative chronic myeloproliferative disorders, and from the lack of correlation between plasma serglycin and lysozyme. 19 However, a statistically significant correlation between plasma serglycin and neutrophil elastase was found (Figures 2c and d) . This may reflect the role of serglycin in targeting of neutrophil elastase to granules. 3 Serglycin is previously reported to be present in granules of cytotoxic lymphocytes in complex with granzyme B and perforin, 14 and localization of granzyme B in granules of cytotoxic lymphocytes is reported to be dependent on serglycin. 15 We were unable to detect immunoreactivity for serglycin in bone marrow specimens from patients with B-or T-ALL (Figures 1i-l) . To further investigate whether the malignant counterparts of cytotoxic lymphocytes were positive for serglycin immunoreactivity, we tested specimens from NK-cell lymphomas and ALCL 21 for serglycin by immunohistochemistry. No staining for serglycin was detectable (Figure 3) . Still, these specimens were positive for granzyme B, which has been reported to be dependent on serglycin for localization to granules. 15 We cannot rule out that the granzyme B level is reduced in these tumor cells compared with their normal counterparts but clearly granzyme B is present in the absence of serglycin. This shows that serglycin cannot be essential for packaging of granzyme B in granules in these tumor cells but it does not rule out serglycin as essential for routing granzyme B to granules. However, this would require that tumor stem cells that express serglycin exist. The previous report on granzyme B dependency on serglycin for granule localization is from a murine model. The discrepancy may therefore also be due to differences between the species.
In conclusion, serglycin may be a useful marker in the diagnosis of AML, either as a supplement/alternative to classic markers such as MPO used in characterization of bone marrow specimens or as a marker protein measured in plasma.
